FABP4/5-IN-6 是一种口服有效的强效 FABP4/5 抑制剂(Ki = 0.41/2.53 μM),对 FABP3 的选择性较低(Ki = 59.72 μM),可抑制 Lipopolysaccharides (MS-X54539) (LPS) 诱导的 THP-1 巨噬细胞中 MCP-1 和 IL-6 的分泌,具有显著的抗炎作用并能减轻 LPS 诱导的肝损伤,对 hERG 通道的抑制作用较弱(LD50 > 2000 mg/kg),可用于炎症相关疾病的研究。
产品编号: MS-H23370 CAS No.: 2975215-64-4 分子式: C21H16Cl2FNO3 分子量: 420.26
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价

产品描述

FABP4/5-IN-6 是一种口服有效的强效 FABP4/5 抑制剂(Ki = 0.41/2.53 μM),对 FABP3 的选择性较低(Ki = 59.72 μM),可抑制 Lipopolysaccharides (MS-X54539) (LPS) 诱导的 THP-1 巨噬细胞中 MCP-1 和 IL-6 的分泌,具有显著的抗炎作用并能减轻 LPS 诱导的肝损伤,对 hERG 通道的抑制作用较弱(LD50 > 2000 mg/kg),可用于炎症相关疾病的研究。

生物实验数据

生物活性 FABP4/5-IN-6 is an orally active and potent FABP4/5 inhibitor (Ki = 0.41/2.53 μM) with low selectivity over FABP3 (Ki = 59.72 μM) that inhibits Lipopolysaccharides (MS-X54539) (LPS)-induced secretion of MCP-1 and IL-6 in THP-1 macrophages, exhibits significant anti-inflammatory effects and alleviates LPS-induced liver injury, shows weak inhibition of the hERG channel (LD50 > 2000 mg/kg), and can be used for research on inflammation-related diseases.
体外研究
(In Vitro)

FABP4/5-IN-6 (Compound Y18) (80 μM, 24 h) shows no significant cytotoxicity to THP-1 cells, and cell viability is unaffected.
FABP4/5-IN-6 (5-25 μM, 24 h) significantly inhibits LPS-induced secretion of MCP-1 and IL-6 in THP-1 macrophage cells, with the inhibitory effect showing a dose-dependent effect.

ELISA Assay

Cell Line: LPS-induced THP-1 macrophage cells
Concentration: 5 μM, 10 μM, 25 μM
Incubation Time: Incubate 18 hours, then stimulate with LPS (100 ng/mL) for 6 hours
Result: Significantly reduced the secretion of MCP-1 and IL-6.
体内研究
(In Vivo)

FABP4/5-IN-6 (Compound Y18) (50 mg/kg,口服,每日一次,连续4天) 在小鼠体内表现出显著的抗炎和保护作用。它能有效减轻 LPS 诱导的肝损伤,抑制全身和局部肝脏炎症反应,并改善肝脾的病理损伤。

Animal Model: Seven-week-old male C57BL/6 mice were used to develop an acute inflammation model induced by LPS.
Dosage: 50 mg/kg
Administration: P.o., once daily for 4 days, LPS was injected 30 minutes after the last dose
Result: Body weight remained unchanged.
Significantly reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.
Significantly inhibited LPS-induced MCP-1 elevation.
Exhibited a trend toward reducing serum IL-6 and TNF-α levels.
Reduced inflammatory cell infiltration and alleviated pathological changes in the spleen.
Significantly inhibited the LPS-induced upregulation of liver MCP-1 and CD11b (macrophage marker) gene expression, and showed an inhibitory trend on IL-6 and TNF-α gene expression.

化学信息

分子量 420.26
分子式 C21H16Cl2FNO3
CAS No. 2975215-64-4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础